Frédérique Spyratos

3.2k citations

41 papers · 1.7k indexed · h-index 24

Cancer Research top 2%
- Breast Cancer Treatment Studies 12
- Cancer Genomics and Diagnostics 8
Oncology top 5%
- HER2/EGFR in Cancer Research 11
- Cancer Cells and Metastasis 6
- Cancer Treatment and Pharmacology 4
Immunology and Allergy top 5%
Molecular Biology top 10%
- Epigenetics and DNA Methylation 4
- Single-cell and spatial transcriptomics 3
Pathology and Forensic Medicine top 10%
Genetics
- Estrogen and related hormone effects 11

Co-authors: K. Hacène M. Tubiana-Hulin Rosette Lidereau Jacques Rouëssé Catherine Andrieu Ivan Bièche Martine Trassard A Desplaces
Cited by: Cancer Research Oncology Immunology and Allergy
Partner nations: France United States Switzerland

In The Last Decade

Frédérique Spyratos

41 papers receiving 1.7k citations

Peers

Countries citing papers authored by Frédérique Spyratos

Since Specialization

Citations

This map shows the geographic impact of Frédérique Spyratos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frédérique Spyratos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frédérique Spyratos more than expected).

Fields of papers citing papers by Frédérique Spyratos

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frédérique Spyratos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frédérique Spyratos. The network helps show where Frédérique Spyratos may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Frédérique Spyratos, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frédérique Spyratos Line = papers co-authored together Frédérique Spyratos links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	PIK3R1 underexpression is an independent prognostic marker in breast cancer Magdalena Čížková,Sophie Vacher,Didier Meseure,Martine Trassard,A. Susini,Dana Mlcuchova,Céline Callens,Étienne Rouleau,Frédérique Spyratos,Rosette Lidereau,Ivan Bièche	2013	97
2	Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy Ivan Bièche,Sophie Vacher,François Lallemand,Sengül Tozlu-Kara,H. Bennani,M. Beuzelin,Keltouma Driouch,Étienne Rouleau,Florence Lerebours,Hugues Ripoche,Géraldine Cizeron-Clairac,Frédérique Spyratos,Rosette Lidereau	2011	58
3	CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients Dimo Dietrich,Manuel Krispin,Jörn Dietrich,Anne Faßbender,Jörn Lewin,Nadia Harbeck,Manfred Schmitt,Serenella Eppenberger‐Castori,Vincent Vuaroqueaux,Frédérique Spyratos,John A. Foekens,Ralf Lesche,John W.M. Martens	2010	40
4	DNA Methylation Markers Predict Outcome in Node-Positive, Estrogen Receptor-Positive Breast Cancer with Adjuvant Anthracycline-Based Chemotherapy Oliver Hartmann,Frédérique Spyratos,Nadia Harbeck,Dimo Dietrich,Anne Faßbender,Manfred Schmitt,Serenella Eppenberger‐Castori,Vincent Vuaroqueaux,Florence Lerebours,Katrin Welzel,Sabine Maier,Achim Plum,Stephan Niemann,John A. Foekens,Ralf Lesche,John W.M. Martens	2008	79
5	Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer Sandra E. Ghayad,Julie A. Vendrell,Ivan Bièche,Frédérique Spyratos,Charles Dumontet,Isabelle Treilleux,Rosette Lidereau,Pascale A. Cohen	2008	55
6	DNA-methylation of the homeodomain transcription factor PITX2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients – Technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) PathoBiology group Sabine Maier,Inko Nimmrich,Thomas Koenig,Serenella Eppenberger‐Castori,Inga Bohlmann,Angelo Paradiso,Frédérique Spyratos,Christoph Thomssen,Volkmar Mueller,Jörg Nährig,Francesco Schittulli,Ronald Kates,Ralf Lesche,Ina Schwope,Antje Kluth,Almuth Marx,John W.M. Martens,John A. Foekens,Manfred Schmitt,Nadia Harbeck	2007	93
7	Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. M. Tubiana-Hulin,Véronique Becette,Ivan Bièche,L. Mauriac,Gilles Romieu,Frédéric Bibeau,Gaëtan MacGrogan,Hugues Bourgeois,P. Chollet,Rémy Defrance,Frédérique Spyratos	2007	17
8	Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome Vincent Vuaroqueaux,Patrick Urban,Martin Labuhn,Mauro Delorenzi,Pratyaksha Wirapati,Christopher C. Benz,Renata Flury,Holger Dieterich,Frédérique Spyratos,Urs Eppenberger,Serenella Eppenberger‐Castori	2007	52
9	Altered expression pattern of alternatively spliced estrogen receptor β transcripts in breast carcinoma Igor Girault,Catherine Andrieu,Sengül Tozlu,Frédérique Spyratos,Ivan Bièche,Rosette Lidereau	2004	26
10	Luteinizing hormone receptor status and clinical, pathologic, and prognostic features in patients with breast carcinomas Geri Méduri,Nathalie Charnaux,Frédérique Spyratos,K. Hacène,Hugue Loosfelt,Edwin Milgröm	2003	23
11	Correlation between MIB‐1 and other proliferation markers Frédérique Spyratos,M. Ferrero-Poüs,Martine Trassard,K. Hacène,Edelmira Phillips,M. Tubiana-Hulin,V Le Doussal	2002	152
12	Flow cytometric S‐phase fraction measurement in breast carcinoma: Influence of software and histogram resolution Marie‐Lise Jourdan,M. Ferrero-Poüs,Frédérique Spyratos,Sylvie Romain,Pierre‐Marie Martin,Agnès Chassevent	2002	15
13	The CGA gene as new predictor of the response to endocrine therapy in ERα-positive postmenopausal breast cancer patients Ivan Bièche,Béatrice Parfait,Catherine Noguès,Catherine Andrieu,Dominique Vidaud,Frédérique Spyratos,Rosette Lidereau,Michel Vidaud	2001	17
14	Improvement of quality control for steroid receptor measurements: Analysis of distributions in more than 40000 primary breast cancers Sylvie Romain,Frédérique Spyratos,J Goussard,Jean–Louis Formento,H Magdelénat,(unknown)	1996	9
15	DNA content and cell cycle analysis by flow cytometry in clinical samples: Application in breast cancer Frédérique Spyratos	1993	10
16	Evaluation of breast carcinoma chemosensitivity by flow cytometric DNA analysis and computer assisted image analysis M Briffod,Frédérique Spyratos,K. Hacène,M. Tubiana-Hulin,C. Pallud,Frédéric Gilles,Jacques Rouëssé	1992	25
17	Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors Magali Ferrero,Frédérique Spyratos,Viviane Le Doussalg,A Desplaces,Jacques Rouëssé	1990	34
18	Epidermal growth factor receptors and prognosis in primary breast cancer Frédérique Spyratos,J Delarue,Catherine Andrieu,Rosette Lidereau,M.H. Champème,K. Hacène,M Brunet	1990	47
19	Cell‐cycle studies by multiparametric automatic scanning of topographically preserved cells in culture Evelyne Colomb,F Kopp,Frédérique Spyratos,Pierre‐Marie Martin	1989	9
20	Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. Cytomorphologic changes, initial tumor ploidy, and tumor regression M Briffod,Frédérique Spyratos,M. Tubiana-Hulin,C. Pallud,Claude Mayras,Annie Filleul,Jacques Rouëssé	1989	48

About Frédérique Spyratos

Frédérique Spyratos is a scholar working on Cancer Research, Oncology and Genetics, having authored 41 papers that have together received 1.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (12 papers), Estrogen and related hormone effects (11 papers), HER2/EGFR in Cancer Research (11 papers), Cancer Genomics and Diagnostics (8 papers), Cancer Cells and Metastasis (6 papers), Epigenetics and DNA Methylation (4 papers), Cancer Treatment and Pharmacology (4 papers) and Single-cell and spatial transcriptomics (3 papers). The work is most often cited by research in Cancer Research (788 citations), Oncology (660 citations) and Immunology and Allergy (127 citations). Frédérique Spyratos has collaborated with scholars based in France, United States and Switzerland. Frequent co-authors include K. Hacène, M. Tubiana-Hulin, Rosette Lidereau, Jacques Rouëssé, Catherine Andrieu, Ivan Bièche, Martine Trassard, A Desplaces, M Brunet and M. Ferrero-Poüs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact